MycoBiomDB – Record Details (MyCo_3158)

Biomarker Record Details

Database ID: MyCo_3158
DB IDMyCo_3158
TitleInvasive rhino-orbital-cerebral aspergillosis in an immunocompetent patient
Year2020
PMID32507472
Fungal Diseases involvedRhino-orbital-aspergillosis
Associated Medical ConditionNone
GenusAspergillus
Speciesspp.
OrganismAspergillus spp.
Ethical StatementNone
Site of InfectionNone
Opportunistic invasiveNone
Sample typeBody fluid
Sample sourceSerum
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NameBDG
Biomarker Full Name1-3-beta-D-Glucan
Biomarker TypeDiagnostic
BiomoleculeProtein
Geographical LocationFrance
CohortA 61-year-old patient with a history of arterial hypertension, gout and well-controlled diabetes treated by simple diet (last HbA1c: 5.9%) presented in January 2016 with a severe sudden decrease in right visual acuity associated with painless diplopia without exophthalmia, was included in the study.
Cohort No.1
Age Group61
P ValueNone
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismRhino-orbital (ROA) or sino-orbital aspergillosis is a disease with a poor prognosis, which is rarely described in immunocompetent patients. Diagnosis of the disease is often delayed due to the absence of specific clinical signs and the anatomically deep localization of the infection. Furthermore, ROA can mimic a neoplastic aetiology or vasculitis resulting in the use of corticoste- roids, which may facilitate progression of the disease.
TechniqueELISA
Analysis MethodFDA Approved-Fungitell assay
ELISA kitsELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad Laboratories, Redmond, WA, USA)
Assay DataFDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA
Validation Techniques usedFDA Approved-Fungitell assay
Up Regulation Down RegulationPositive
Sequence DataNone
External LinkNone